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Abstract
Purpose—To report the ocular phenotype in patients with autosomal recessive bestrophinopathy 
and carriers, and to describe novel BEST1 mutations.
Methods—Patients with clinically suspected and subsequently genetically proven autosomal 
recessive bestrophinopathy underwent full ophthalmic examination and investigation with fundus 
autofluorescence imaging, spectral domain optical coherence tomography, electroretinography, 
and electrooculography. Mutation analysis of the BEST1 gene was performed through direct 
Sanger sequencing.
Results—Five affected patients from four families were identified. Mean age was 16 years 
(range, 6–42 years). All affected patients presented with reduced visual acuity and bilateral, 
hyperautofluorescent subretinal yellowish deposits within the posterior pole. Spectral domain 
optical coherence tomography demonstrated submacular fluid and subretinal vitelliform material 
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in all patients. A cystoid maculopathy was seen in all but one patient. In 1 patient, the location of 
the vitelliform material was seen to change over a follow-up period of 3 years despite relatively 
stable vision. Visual acuity and fundus changes were unresponsive to topical and systemic 
carbonic anhydrase inhibitors and systemic steroids. Carriers had normal ocular examinations 
including normal fundus autofluorescence. Three novel mutations were detected.
Conclusion—Three novel BEST1 mutations are described, suggesting that many deleterious 
variants in BEST1 resulting in haploinsufficiency are still unknown. Mutations causing autosomal 
recessive bestrophinopathy are mostly located outside of the exons that usually harbor vitelliform 
macular dystrophy–associated dominant mutations.
Keywords
autosomal recessive bestrophinopathy; BEST1 gene; deleterious mutations; vitelliform
BEST1 (VMD2) is a gene located on the long arm of chromosome 11 (11q12.3) that encodes 
for the 585 amino acid transmembrane protein bestrophin 1, located on the basolateral 
aspect of retinal pigment epithelial (RPE) cells.1 The exact function of bestrophin 1 is still 
not unequivocally characterized, but it is linked to transepithelial chloride flow possibly by 
controlling Ca2+ channels in the RPE.1–3 Mutations in BEST1 therefore affect RPE 
metabolism, and by consequence outer retinal function with which the RPE is intimately 
associated. Over 200 mutations in BEST1 have been identified and published.1,3,4 Mutations 
are associated with Best vitelliform macular dystrophy (VMD, MIM 153700), adult-onset 
vitelliform macular dystrophy (MIM 608161), retinitis pigmentosa 50 (RP50, MIM 613194), 
and autosomal dominant vitreoretinochoroidopathy (MIM 193220). These diseases are all 
caused by autosomal dominant mutations. Recently, a phenotype caused by autosomal 
recessive mutations in BEST1 was described: autosomal recessive bestrophinopathy (ARB, 
OMIM 611809).
Autosomal recessive bestrophinopathy is a rare ocular disease. It was defined by Burgess et 
al1 in 2008, although the same condition with compound heterozygous mutations in VMD2 
had been described 2 years earlier.5 It results from biallelic mutations in BEST1 and is 
characterized by a multifocal vitelliform dystrophy with subretinal fluid. An association 
with hypermetropia and angle closure has been described.1 Herein, we review the clinical 
features and mutation analysis of four families with ARB.
Materials and Methods
Patients and Clinical Analyses
All patients underwent a complete ophthalmic examination by a retinal physician. This 
included best-corrected visual acuity, cycloplegic refraction, slit-lamp biomicroscopy, and 
dilated funduscopy. All patients underwent color fundus photography, fundus 
autofluorescence imaging, and spectral domain optical coherence tomography. In addition, 
Patient 4 underwent fluorescein and indocyanine green angiography. When possible, 
patients had electroretinography and electrooculography performed under the International 
Society for Clinical Electrophysiology of Vision standards.6,7 Peripheral blood was drawn 
for genetic testing. Patients provided written informed consent for all procedures, which 
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were approved by the Ethics Committees of the sites involved and adhered to the 
Declaration of Helskinki (Institutional Review Board protocol #AAAB6560 Columbia 
University).
Genetic Analyses
All 11 exons of BEST1 gene were sequenced by Sanger direct sequencing method to obtain 
sequences for all coding sequences, the noncoding Exon 1, and 50bp of adjacent intronic 
sequences of each exon. Primer sequences are available on request. Messenger RNA was 
isolated from venous blood using QIAamp RNA Blood Mini Kit (QIAGEN Cat. No. 75142) 
with a fast spin-column procedure. Genomic DNA is eliminated by pre-treating the RNA 
sample with DNase I, Amplification Grade (Invitrogen Cat. No. 18068-015 DNase I 
Amplification Grade; Invitrogen, Carlsbad, CA). The primer pair was designed to 
encompass BEST1 Exons 1 and 2. Forward primer was in the Exon 1 of BEST1, 
5′ACCAGCCTAGTCGCCAGA3′ (1) and the reverse primer in the Exon 2 of BEST1, 
5′GCGGATGATGTAGTAGCAGAG3′ (2). The final concentration for each primer was 0.2 
μmol. The thermal cycling conditions were established using a ABI 9700 thermocycler 
(Applied Biosystems, Foster City, CA). Efficient complementary DNA synthesis was 
achieved in a 30-minute incubation at 55° C. Polymerase chain reaction (PCR) amplification 
consisted of 40 cycles of 94°C for 15 seconds, 65° C for 30 seconds, and 68°C for 1 minute. 
We used 1 cycle 68°C for 5 minutes for final extension.
Results
Five patients from four families with genetically confirmed ARB were identified. Mean age 
was 16 years (range, 6–42 years). Two patients (Patients 3 and 5) were the product of a 
consanguineous marriage. All patients presented with reduced visual acuity and bilateral, 
subretinal yellowish deposits within the posterior pole that showed increased 
autofluorescence on fundus autofluorescence imaging. On spectral domain optical coherence 
tomography, submacular fluid and subretinal changes suggestive of vitelliform material 
were present in all patients. In 1 patient (Patient 4), the location of the vitelliform material 
was seen to change over a follow-up period of 3 years with relatively stable vision. A 
cystoid maculopathy was seen in all but one patient (Patient 5). Visual acuity and fundus 
changes were unresponsive to topical and systemic carbonic anhydrase inhibitors and 
systemic steroids. Both parents of Patient 3 had normal ocular examinations including 
normal 20/20 vision, normal fundus autofluorescence, and a completely normal spectral 
domain optical coherence tomography. Clinical features and investigations are described 
below and summarized in Figures 1–4 and Tables 1–3.
Family 1, Patients 1 and 2
A 11-year-old otherwise healthy white boy presented with a 6-month history of reduced 
vision and central scotoma (Figure 1). His vision was 20/25 in both eyes, and there was no 
evidence of angle closure. Bilateral, multifocal subretinal hyperautofluorescent yellowish 
deposits extended from the posterior poles up to the equator. Cystoid macular edema and 
shallow serous macular detachments were present in both eyes. Treatment with topical 
nepafenac 0.1% (1 month) and prednisone 10 mg PO (3 weeks) failed to improve vision or 
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the fundus appearance. His 7-year-old brother was subsequently found to have almost 
identical clinical findings, whereas his 9-year-old sister and parents were unaffected.
Compound heterozygous BEST1 variants were identified in the affected patients. The first 
was a novel c.728C>A; p.Ala243Glu missense mutation in Exon 7. In the same codon, 
previously reported BEST1 variants include p.Ala243Val8 and p.Ala243Thr.9 Both the 
nucleotide and the amino acid are highly conserved in this position of BEST1. All predictive 
programs suggest that the variant is disease-causing or disease-damaging. Therefore, it is 
highly likely that this variant is deleterious as are (almost) all BEST1 variants implicated in 
ARB. The second mutation, the previously described c.598C>T; p.Arg200* mutation,1 
generates a stop codon and results in a truncated protein at position 200.
Family 2, Patient 3
A 6-year-old asymptomatic, U.S.–born African boy was noted to have poor vision by his 
schoolteacher (Figure 2). A history of consanguinity was present in the family, with his 
parents being first cousins. Bilateral, multifocal curvilinear subretinal hyperautofluorescent 
yellowish deposits were present in both eyes with cystic edema and subretinal fluid at the 
maculae. Subfoveal choroidal thicknesses were 586 μm in the right eye and 482 mm in the 
left eye. Trials of topical dorzolamide 2% 3 times a day in both eyes (6 weeks), 
acetazolamide 500 mg nocte (2 months), and prednisone failed to improve vision or the 
clinical appearance. Three years after first presentation, the vision remained stable at 20/80 
in both eyes. All other family members were clinically unaffected.
A novel, homozygous deleterious mutation was identified in the proband in the in-frame 
deletion of 3 nucleotides, c.847_849delTTC, which results in a homozygous deletion of 
phenylalanine at position 283, p.Phe283del.
Family 3, Patient 4
A 12-year-old otherwise healthy, emmetropic Puerto Rico–born U.S. boy was noted to have 
reduced vision on routine eye examination. Bilateral, confluent curvilinear subretinal 
hyperautofluorescent yellowish vitelliform deposits became more multifocal and dispersed 
over 3 years of follow-up (Figure 3). Bilateral multifocal serous retinal detachments and 
cystic edema involved both maculae. Subfoveal choroidal thickness was 537 μm in the right 
eye and 527 μm in the left eye. Oral prednisone 60 mg daily (3 months), topical dorzolamide 
2% 3 times a day in both eyes (6 weeks), and oral acetazolamide (6 weeks) were trialed to 
reduce the cystoid maculopathy with no clinical response.
A previously described10 homozygous c.821C>G; p.Pro274Arg variant was detected. This 
variant of a highly conserved nucleotide and an amino acid is predicted to be deleterious by 
all predictive programs.
Family 4, Patient 5
A 42-year-old woman whose vision problems started at 5 years of age was recently noticing 
deteriorating central vision (Figure 4). She was the product of a first-cousin marriage. A 
white-yellow vitelliform lesion was present at the left fovea, and RPE and retinal atrophy 
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within the posterior poles. Shallow subretinal but not intraretinal fluid was present at both 
maculae. Subfoveal choroidal thickness was 370 μm in both eyes. A trial of oral 
acetazolamide 500 mg failed to improve the vision.
A splice site variant, c.-29+5G>A (IVS1+5G>A), was identified in Intron 1 of BEST1 in the 
donor site of the first untranslated exon. This exon is usually not screened for variants in 
patients with BEST1-associated diseases. As shown in Table 3, the variant practically 
abolishes the splice donor site as predicted by all programs. To confirm the functional 
consequences of this variant, we performed the splicing studies through an “illegitimate 
transcript” strategy. Although the BEST1 gene is expressed only in the retinal pigment 
epithelium, it can also be detected by PCR at very low levels from other cells, such as the 
leucocytes in peripheral blood. We isolated messenger RNA from a blood sample of Patient 
5 and performed PCR encompassing two exons. As seen in Figure 5, the messenger RNA of 
a normal control produced the expected PCR fragment in the situation where the splicing 
had been performed correctly. In this patient, homozygous for the IVS1+5G>A variant, the 
expected PCR product of 234bp was not detected and it was clear that the splicing of BEST1 
gene was incorrect, very likely resulting in no functional messenger RNA and, consequently, 
no BEST1 protein.
Discussion
Autosomal recessive bestrophinopathy is a rare disease, with only a few case series 
described.1,5,10,12–17 The timing of presentation is variable, with patients as young as 3 
years10 and as old as 45 years13 being reported. Patients are typically hyperopic and present 
with moderately reduced vision, bilateral multifocal hyperautofluorescent vitelliform lesions 
with foveal involvement, and shallow retinal detachment. Scotopic and photopic full-field 
electroretinographies usually diminish with age, and the electrooculography shows a 
reduced or absent light rise (Arden ratio 1.0).
Our patients’ phenotypes are all very consistent with these previous reports of ARB, 
although some interesting observations can be made. In one case (Patient 1), the vitelliform 
material appeared to emanate from the RPE on spectral domain optical coherence 
tomography. In 3 patients (Patients 1, 3, and 4), the retinal architecture was abnormal with 
thickening of Band 2 (traditionally described as the inner segment/outer segment junction), 
even in extramacular attached retina. Although it would be easy to ascribe this to vitelliform 
material, this area of “Band 2” thickening did not uniformly hyperautofluoresce and may 
instead represent elongation of degenerate photoreceptors. In four patients (Patients 1–4), 
the presence of a cystoid maculopathy was striking. This had been reported 
previously10,12,13,16,17 and may represent perturbation of the blood–retinal barrier. 
Inflammation is less likely given the lack of anterior chamber or vitreous cells, optic 
neuritis, or vasculitis in all these patients. This cystic edema was absent in the eldest patient 
(Patient 5, 42 –years old). It is possible that with time, the multifocal vitelliform material in 
pediatric cases of ARB resolves. Subfoveal choroidal thickness was measured by enhanced 
depth imaging optical coherence tomography in three patients (Patients 3–5), with 
thickening in Patient 5. Unfortunately, not only has choroidal thickness not been described 
in ARB before, but normative data only apply to adults19 and are lacking in the pediatric 
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population. It is therefore difficult to determine if the choroidal thickness was pathologic in 
Patients 3 and 4.
Patient 4 had a 3-year follow-up and demonstrated dispersion and a change in location of the 
vitelliform material from superior to nasal to the optic disks. This is one of the longest 
follow-ups of a patient with ARB that we are aware of, and the first to describe fluctuation 
and dispersion in appearance. This patient also had indocyanine green angiography, which 
has only been described once before in ARB.15 There was bilateral midphase 
hyperfluorescence at both maculae, which colocalized with the area of fluorescein leakage. 
This may represent leakage of indocyanine green dye into the shallow neurosensory 
detachments or choroidal hyperpermeability. Lipofuscin-rich vitelliform material does not 
normally stain with indocyanine green dye.20 In VMD, which has similarities to ARB, 
small, peripheral hyperfluorescent spots on indocyanine green angiography have been 
described,20 and histopathology has shown involvement not only of the retina and RPE but 
also of fibrillar material and electron-dense particles on electron microscopy within the 
choroid.21,22
Attempts at managing the cystic macular changes with topical and systemic carbonic 
anhydrase inhibitors and systemic steroids proved unsuccessful. However, it must be 
emphasized that the medications, dosages, and durations were not standardized, and Patient 
2 was not prescribed any treatment.
We identified 3 novel BEST1 mutations (c.728C>A [p.Ala243Glu] in Family 1, c.
847_849delTTC [p.Phe283-del] in Patient 3, and IVS1+5G>A in Patient 5), suggesting that 
many deleterious variants in BEST1 resulting in loss of function are still unknown. It has 
been hypothesized that the ARB phenotype is caused by mutations that occur in the 
intracellular loop of the protein10 or that the presence of two null alleles lead to disease. We 
agree that autosomal recessive mutations in BEST1 that lead to ARB are most likely 
deleterious while autosomal dominant mutations in BEST1 lead to VMD because of a 
dominant negative effect. Based on our results and reviewing those previously described, we 
also suggest that the dominant and recessive mutations mostly do not overlap and that the 
recessive mutations are located throughout the gene.
Other conditions can mimic the phenotypic appearance of ARB. These include multifocal 
Best disease, adult-onset VMD, multifocal pattern dystrophy associated with peripherin/RDS 
mutations, acute, exudative polymorphous vitelliform maculopathy, and paraneoplastic 
syndromes or metastases.23–26 In addition, chronic, central serous choroidopathy can present 
with serous retinal detachments, cystoid maculopathy, and subretinal fibrin, although fibrin 
does not hyperautofluoresce. Boon et al23 studied clinical and genetic heterogeneity in 15 
patients with a multifocal vitelliform phenotype. Nine of these patients carried a BEST1 
mutation and one a peripherin/RDS mutation. Not only were the phenotypic appearance of 
patients with BEST1 mutations diverse, but some of the patients without mutations in BEST1 
presented with a fundus appearance identical to the patients we describe in this study. 
Incorrect initial diagnoses in our patients included acute exudative polymorphous vitelliform 
maculopathy, Vogt–Koyanagi–Harada disease, and fundus flavimaculatus. Comprehensive 
FUNG et al. Page 6
Retina. Author manuscript; available in PMC 2015 May 09.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
screening by sequencing of the entire BEST1 gene is therefore essential for the correct 
classification of these patients.
In summary, we report five patients from four families where affected individuals presented 
with ARB. Genetic analyses confirmed the disease in all families and showed segregation of 
likely deleterious, homozygous, or compound heterozygous mutations in BEST1 with the 
disease phenotype. This study highlights several important points for the management of 
ARB:
1. Visual acuity remains relatively stable, although the fundus vitelliform pattern may 
fluctuate and diminish with time
2. Subretinal fluid and cystoid macular changes associated with ARB do not respond 
to topical and systemic carbonic anhydrase inhibitors or systemic steroids
3. Three of the five mutations were novel, suggesting that many deleterious variants 
in BEST1 resulting in loss of function are still unknown
4. Sequencing of the entire gene is required to avoid missing any BEST1 mutations. 
Mutations causing ARB are mostly located outside of the exons that usually harbor 
VMD-associated dominant mutations (Exons 2–6 of BEST1)
5. Mutations causing VMD and ARB rarely overlap. The former have a dominant 
negative effect causing disease phenotype in a heterozygous state. The latter delete 
the BEST1 protein but do not cause the disease in heterozygosity, because carriers 
of recessive BEST1 mutations (all parents and some siblings of ARB cases) have a 
normal phenotype
6. Because the phenotype of ARB may mimic other diseases, molecular genetic 
confirmation of mutations in BEST1 is required to confirm the diagnosis.
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Fig. 1. 
Family 1, Patient 1. A 11-year-old otherwise healthy white boy presented with a 6-month 
history of reduced vision and central scotoma. A. Color fundus photographs demonstrate 
bilateral, multifocal subretinal yellowish deposits within the posterior pole extending up to 
the equator. B. There is intense hyperautofluorescence (Topcon TRC-50DX retinal camera; 
Topcon America, Paramus, NJ) of the yellowish deposits and moderate 
hyperautofluorescence in the areas of subretinal fluid. C. Spectral domain optical coherence 
tomography (Topcon 3D-OCT 2000) horizontal scans through the maculae reveal cystoid 
macular changes and shallow serous macular detachments in both eyes. There is thickening 
and hyperreflectivity at the inner segment/outer segment photoreceptor junction (“Band 2,” 
arrows). D. Spectral domain optical coherence tomography horizontal scan through the 
superior vascular aracade, 3 months after presentation colocalizes the vitelliform material to 
the subretinal space. The material appears to be emanating from the RPE (stars). E. Genetic 
screening of the family members confirmed the segregation of the two BEST1 mutations 
with the disease.
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Fig. 2. 
Family 2, Patient 3. A 6-year-old asymptomatic, U.S.–born African boy was noted to have 
poor vision by his schoolteacher. A. Color montage fundus photographs. In the right eye, 
there is subtle vitelliform material nasal to the optic disk. In the left eye, multifocal, 
curvilinear subretinal yellowish deposits are seen along the superotemporal arcade. B. 
Fundus autofluorescence imaging (Topcon TRC-50DX retinal camera; Topcon America) 
demontrates hyperautofluorescence of the vitelliform material in the left eye. C. Enhanced 
depth imaging spectral domain optical coherence tomography (Heidelberg Spectralis HRA
+OCT; Heidelberg Engineering Inc, Heidelberg, Germany) demonstrates bilateral shallow 
subretinal fluid involving the maculae, a cystoid maculopathy, and subfoveal choroidal 
thicknesses of 586 μm in the right eye and 482 μm in the left eye. There is thickening and 
hyperreflectivity at the inner segment/outer segment photoreceptor junction (“Band 2,” 
arrows). D. The consanguineous parents had normal retinal examinations, 20/20 vision in 
both eyes and normal quantitative fundus autofluorescence imaging. Two older brothers and 
one sister, who were not available for genetic screening, were visually asymptomatic with 
20/20 vision in both eyes.
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Fig. 3. 
Family 3, Patient 4. A 12-year-old otherwise healthy, emmetropic Puerto Rico-born U.S. 
boy was noted to have reduced vision on routine eye examination. A. Montage color fundus 
photographs at initial presentation. There are bilateral, confluent curvilinear subretinal 
yellowish vitelliform deposits superior to the optic disks, along the temporal vascular 
arcades and encircling the maculae. B and C. Color fundus photographs 3 years later. The 
vitelliform material has become more multifocal and dispersed to involve the nasal retinae. 
Visual acuities remained stable at 20/60 in the right eye and 20/70 in the left eye. D. Fundus 
autofluorescence imaging (Topcon TRC-50DX retinal camera; Topcon America) 
demonstrates hyperautofluorescence of the vitelliform material. E. On fluorescein 
angiography (Topcon TRC-50DX; 61 seconds for the right eye, 92 seconds for the left eye), 
there is widespread diffuse hyperfluorescence consistent with pooling in the subretinal space 
and staining of the subretinal yellowish deposits. F. Indocyanine green angiography (Topcon 
TRC-50DX; 11 minutes 43 seconds for the right eye, 12 minutes 7 seconds for the left eye) 
demonstrates bilateral midphase hyperfluorescence at the maculae. G. On spectral domain 
optical coherence tomography (Spectral OCT/SLO; OPKO Instrumentation, Miami, FL), 
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there are bilateral, multifocal serous retinal detachments involving the maculae and cystoid 
changes in the macula. There is thickening and hyperreflectivity at the inner segment/outer 
segment photoreceptor junction (“Band 2”, arrows). Subfoveal choroidal thickness measured 
537 μm in the right eye and 527 μm in the left eye with enhanced depth imaging.
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Fig. 4. 
Family 4, Patient 5. A 42-year-old woman whose vision problems started at 5 years of age 
was recently noticing deteriorating central vision. She was the product of a first-cousin 
marriage. A. Color fundus photographs showing a white–yellow vitelliform lesion at the left 
fovea. There is RPE and retinal atrophy within the posterior poles. B. Fundus 
autofluorescence imaging shows bilateral discrete patches of hypoautofluorescence. The 
vitelliform lesion at the left fovea hyperautofluoresces. C. On spectral domain optical 
coherence tomography (Heidelberg Spectralis HRA+OCT; Heidelberg Engineering Inc), 
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shallow subretinal fluid is seen at both maculae but not cystoid maculopathy. The subretinal 
vitelliform deposit is seen in the left eye. Subfoveal choroidal thickness measured 370 μm in 
both eyes with enhanced depth imaging.
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Fig. 5. 
Analysis of splicing of the BEST1 gene in Patient 5. Complementary DNA from Patient 5, 
harboring the IVS1+5G>A variant (A, Lane 1), and from a normal control individual (A, 
Lane 2) was amplified by primers located in Exons 1 and 2 of the BEST1 gene. 
Amplification of the cDNA of a normal control produced the expected PCR fragment of 
234bp (A, Lane 2). This 234bp PCR fragment corresponds to the correctly spliced fragment 
containing Exons 1 and 2, as shown in the dotted line above in (B). Amplification of the 
cDNA of the patient homozygous for the IVS1+5G>A variant did not yield the expected 
PCR product because the first intron (IVS1) was not spliced out, resulting in a large 1538bp 
PCR product which includes the entire IVS1 (A, Lane 1; B, line below). Lanes 3 and 4 show 
DNA size standards. cDNA, complementary DNA.
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